Vendor Analysis
published on Oct 05, 2021
Report Overview:
This NelsonHall vendor assessment analyzes Conduent's offerings and capabilities in Pharmaceuticals / Life Sciences Operational Transformation
Who is this Report for:
NelsonHall’s pharmaceuticals / life sciences operational transformation profile on Conduent is a comprehensive assessment of Conduent’s offerings and capabilities, designed for:
- Sourcing managers monitoring the capabilities of existing suppliers of pharmaceuticals / life sciences operational transformation services and identifying vendor suitability for operational transformation services RFPs
- Vendor marketing, sales, and business managers looking to benchmark themselves against their peers
- Financial analysts and investors specializing in the pharmaceuticals / life sciences services sector.
Scope of this Report:
The report provides a comprehensive and objective analysis of Conduent’s pharmaceuticals / life sciences operational transformation offerings and capabilities, and market and financial strengths, including:
- Identification of the company’s strategy, emphasis, and new developments
- Analysis of the company’s strengths, weaknesses, and outlook
- Revenue estimates
- Analysis of the profile of the company’s customer base, including the company’s targeting strategy and examples of current contracts
- Analysis of the company’s offerings and key service components
- Analysis of the company’s delivery organization, including the location of delivery locations.
Key Findings & Highlights:
Conduent, which was spun off from Xerox Business Services in 2017, has solutions targeting payer, provider, pharma & life sciences, and government health services. Within its pharma and life sciences business, Conduent currently offers:
- Patient access solutions
- Patient and provider engagement solutions
- Medical information and clinical trial support.
In 2020, Conduent began to re-invest in the pharma & life sciences business. As a result of these investments, Conduent grew the pharmaceutical and life sciences pipeline seven times vs. 2019.